All patients | Patients with A1c≥7.3% at baseline | |||
QIIP (N=406) (%) | Control (N=403) (%) | QIIP (N=153) (%) | Control (N=157) (%) | |
Comorbidity | 95.8 | 95.8 | 98.0 | 95.5 |
Diabetes-related complication | 54.7 | 53.9 | 56.9 | 58.6 |
Comorbidity | ||||
Hypertension* | 68.7 | 67.3 | 66.0 | 70.1 |
Dyslipidemia†,‡ | 88.7 | 81.9 | 92.2 | 82.8 |
Depression§ | 18.0 | 13.9 | 24.8 | 12.7 |
Obesity | 26.6 | 30.5 | 28.8 | 36.3 |
Arthritis | 21.9 | 14.1 | 24.2 | 15.3 |
Respiratory disease | 12.3 | 15.9 | 10.5 | 10.2 |
Hypothyroid | 6.7 | 7.2 | 5.9 | 8.9 |
Diabetes-related complications | ||||
Cardiovascular disease | 31.3 | 26.6 | 35.3 | 29.3 |
Nephropathy | 15.3 | 14.4 | 14.4 | 19.1 |
Neuropathy | 8.1 | 8.2 | 11.1 | 10.2 |
Retinopathy | 5.7 | 3.5 | 9.2 | 4.5 |
Other eye disease | 17.5 | 21.3 | 17.0 | 15.9 |
Diabetic foot disease | 0.5 | 2.5 | 0.7 | 2.6 |
Amputations | 1.2 | 0.7 | 3.3 | 0.6 |
Skin disease | 2.5 | 0.7 | 1.3 | 0 |
Erectile dysfunction | 6.9 | 8.9 | 8.5 | 9.6 |
Other | 28.8 | 24.3 | 28.1 | 19.8 |
*Definition: condition documented in chart; when adding whether antihypertensive medication prescribed the total=90.5% (732/809), QIIP=92.1% (374/406), control=88.8% (358/403).
†Significant for the subset of patients above study target A1c, p=0.004.
‡Definition: condition documented in chart and/or antihypertensive/lipid-lowering medication prescribed.
§Significant for all patients and the subset of patients above study target A1c, p=0.03.
QIIP, Quality Improvement and Innovation Partnership.